Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics Inc (SLNO) reports a strong initial market response to Vykat XR despite a significant net loss and high operational expenses in Q1 2025.

Investing.com -- Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares gained 2.6% after the biopharmaceutical company provided an update on the U.S. launch of its newly approved drug VYKAT XR and reported ...

California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical and clinical-stage ...

Pipeline programs: Design continues to progress preclinical activities for its myotonic dystrophy type-1 (DM1) program toward the selection of a development candidate later in 2025. In Huntington's ...